Tumor-associated macrophages in breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 7, Issue 2, 2002, Pages 177-189

  Leek, Russell D ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Angiogenesis; Breast; Hypoxia; Macrophage; Metastasis; Tumor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CATHEPSIN D; COLONY STIMULATING FACTOR 1; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYALURONIDASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; THYMIDINE PHOSPHORYLASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; COLONY FORMING UNIT GM; CYTOTOXIC T LYMPHOCYTE; EXTRACELLULAR MATRIX; HYPOXIA; KUPFFER CELL; METASTASIS; MITOGENESIS; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; WOUND HEALING; ANIMAL; BREAST TUMOR; HUMAN; MACROPHAGE; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; HUMANS; MACROPHAGES;

EID: 0005339099     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020304003704     Document Type: Review

References (119)

1. R. D. Leek, A. L. Harris, and C. E. Lewis (1994). Cytokine networks in solid human tumors: Regulation of angiogenesis. J. Leukoc. Biol. 56:423-435.
2. R. D. Leek, C. E. Lewis, and A. L. Hariss (1997). The role of macrophages in tumor angiogenesis. In R. Bicknell and C. E. Lewis (eds.), Tumor Angiogenesis, Oxford University Press, Oxford.
3. M. Crowther, N. J. Brown, E. T. Bishop, and C. E. Lewis (2001). Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol. 70:478-490.
4. B. Bottazzi, N. Polentarutti, R. Acero, A. Balsari, D. Boraschi, P. Ghezzi, M. Salmona, and A. Mantovani (1983). Regulation of the macrophage content of neoplasms by chemoattractants. Science 220:210-212.
5. D. T. Graves and A. J. Valente (1991). Monocyte chemotactic proteins from human tumor cells. Biochem. Pharmacol. 41:333-337.
6. R. D. Leek, C. E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, and A. L. Harris (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56:4625-4629.
7. M. J. Auger and J. A. Ross (1992). The biology of the macrophage. In C. E. Lewis and J. O. D. McGee (eds.), The Macrophage, Oxford University Press, Oxford.
8. C. E. Lewis and J. O. D. McGee (1992). The Macrophage, Oxford University Press, Oxford.
9. B. W. Winston, P. M. Krein, C. Mowat, and Y. Huang (1999). Cytokine-induced macrophage differentiation: A tale of 2 genes. Clin. Invest. Med. 22:236-255.
10. A. Mantovani (1994). Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab. Invest. 71:5-16.
11. E. Neumark, R. Anavi, I. P. Witz, and A. Ben-Baruch (1999). MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunol Lett. 68:141-146.
12. T. Ueno, M. Toi, H. Saji, M. Muta, H. Bando, K. Kuroi, M. Koike, H. Inadera, and K. Matsushima (2000). Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6:3282-3289.
13. V. Goede, L. Brogelli, M. Ziehe, and H. G. Augustin (1999). Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 82:765-770.
14. Y. X. Fu, J. P. Cai, Y. H. Chin, G. A. Watson, and D. M. Lopez (1992). Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSE Int. J. Cancer 50:585-588.
15. C. Pyke, N. Graem, E. Ralfkiaer, E. Ronne, G. Hoyer-Hansen, N. Brunner, and K. Dano (1993). Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 53:1911-1915.
16. M. Dorsch, H. Hock, U. Kunzendorf, T. Diamantstein, and T. Blankenstein (1993). Macrophage colony-stimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur. J. Immunol. 23:186-190.
17. Y. Heike, S. Sone, S. Yano, H. Seimiya, T. Tsuruo, and T. Ogura (1993). M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. Int. J. Cancer 54:851-857.
18. S. M. Scholl, R. Lidereau, A. de la Rochefordiere, C. C. Le-Nir, V. Mosseri, C. Nogues, P. Pouillart, and F. R. Stanley (1996). Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res. Treat. 39:275-283.
19. E. Y. Lin, A. V. Nguyen, R. G. Russell, and J. W. Pollard (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727-740.
20. E. R. Stanley, L. J. Guilbert, R. J. Tushinski, and S. H. Bartelmez (1983). CSF-1 - a mononuclear phagocyte lineage-specific hemopoietic growth factor. J. Cell. Biochem. 21:151-159.
21. B. M. Kacinski (1995). CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann. Med. 27:79-85.
22. M. Relf, S. Lejeune, P. A. E. Scott, S. Fox, K. Smith, R. Leek, A. Moghaddam, R. Whitehouse, R. Bicknell, and A. L. Harris (1997). Expression of the angiogenic factors vascular endothelial-cell growth-factor, acidic and basic fibroblast growth-factor, tumor-growth factor-beta-1, platelet-derived endothelial-cell growth-factor, placenta growth-factor, and pleiotrophin in human primary breast-cancer and its relation to angiogenesis. Cancer Res. 57:963-969.
23. M. Clauss, M. Gerlach, H. Gerlach, J. Brett, F. Wang, P. C. Familletti, Y. C. Pan, J. V. Olander, D. T. Connolly, and D. Stern (1990). Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med. 172:1535-1545.
24. R. D. Leek, N. C. Hunt, R. J. Landers, C. E. Lewis, J. A. Royds, and A. L. Harris (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190:430-436.
25. R. D. Leek, R. J. Landers, A. L. Harris, and C. E. Lewis (1999). Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer 79:991-995.
26. A. C. Koong, N. C. Denko, K. M. Hudson, C. Schindler, L. Swiersz, C. Koch, S. Evans, H. Ibrahim, Q. T. Le, D. J. Terris, and A. J. Giaccia (2000). Candidate genes for the hypoxic tumor phenotype. Cancer Res. 60:883-887.
27. A. Lal, H. Peters, B. St Croix, Z. A. Haroon, M. W. Dewhirst, R. L. Strausberg, J. H. Kaanders, A. J. van der Kogel, and G. J. Riggins (2001). Transcriptional response to hypoxia in human tumors. J. Natl. Cancer Inst. 93:1337-1343.
28. M. J. Grimshaw and F. R. Balkwill (2001). Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanism. Eur. J. Immunol. 31:480-489.
29. T. M. Nilsson, A. E. Woods, and A. M. Rofe (1996). In vivo studies of macrophages and intercellular adhesion molecule-1 following lipopolysaccharide treatment in tumor-bearing rats. Immunol. Cell Biol. 74:408-412.
30. D. Nath, A. Hartnell, L. Happerfield, D. W. Miles, J. Burchell, J. Taylor-Papadimitriou, and P. R. Crocker (1999). Macrophage-tumor cell interactions: Identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 98:213-219.
31. V. Shankaran, H. Ikeda, A. T. Bruce, J. M. White, P. E. Swanson, L. J. Old, and R. D. Schreiber (2001). IFNgamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 410:1107-1111.
32. G. Beatty and Y. Paterson (2001). IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166:2276-2282.
33. Y. X. Fu, G. A. Watson, M. Kasahara, and D. M. Lopez (1991). The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I: Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J. Immunol. 146:783-789.
34. C. Menetrier-Caux, G. Montmain, M. C. Dieu, C. Bain, M. C. Favrot, C. Caux, and J. Y. Blay (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778-4791.
35. D. I. Gabrilovich, H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1096-1103.
36. K. A. Backman and P. M. Guyre (1994). Gamma-interferon inhibits Fc receptor II-mediated phagocytosis of tumor cells by human macrophages. Cancer Res. 54:2456-2461.
37. U. Boehm, T. Klamp, M. Groot, and J. C. Howard (1997). Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795.
38. H. Lei, D. W. Ju, Y. Yu, Q. Tao, G. Chen, S. Gu, H. Hamada, and X. Cao (2000). Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma. Gene. Ther. 7:707-713.
39. L. Kaklamanis, R. Leek, M. Koukourakis, K. C. Gatter, and A. L. Harris (1995). Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res. 55:5191-5194.
40. S. E. Webb, J. W. Pollard, and G. E. Jones (1996). Direct observation and quantification of macrophage chemoattraction to the growth factor CSF-1. J. Cell Sci. 109:793-803.
41. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-446.
42. M. Watanabe, P. K. Wallace, T. Keler, Y. M. Deo, C. Akewanlop, and D. F. Hayes (1999). Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res. Treat. 53:199-207.
43. V. Schirrmacher, L. Bai, V. Umansky, L. Yu, Y. Xing, and Z. Qian (2000). Newcastle disease virus activates macrophages for anti-tumor activity. Int. J. Oncol. 16:363-373.
44. J. M. Quinn, J. O. McGee, and N. A. Athanasou (1998). Human tumor-associated macrophages differentiate into osteoclastic bone-resorbing cells. J. Pathol. 184:31-36.
45. C. O'Sullivan, C. E. Lewis, A. L. Harris, and J. O. McGee (1993). Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 342:148-149.
46. C. Sunderkotter, K. Steinbrink, M. Goebeler, R. Bhardwaj, and C. Sorg (1994). Macrophages and angiogenesis. J. Leukoc. Biol. 55:410-422.
47. J. R. Sainsbury, J. R. Farndon, G. K. Needham, A. J. Malcolm, and A. L. Harris (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1:1398-1402.
48. R. J. Steele, O. Eremin, M. Brown, and R. A. Hawkins (1986). Oestrogen receptor concentration and macrophage infiltration in human breast cancer. Eur. J. Surg. Oncol. 12:273-276.
49. G. Mor, W. Yue, R. J. Santen, L. Gutierrez, M. Eliza, L. M. Berstein, N. Harada, J. Wang, J. Lysiak, S. Diano, and F. Naftolin (1998). Macrophages, estrogen and the microenvironment of breast cancer. J. Steroid Biochem. Mol. Biol. 67:403-411.
50. C. I. Chang, J. C. Liao, and L. Kuo (2001). Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 61:1100-1106.
51. J. MacMicking, Q. W. Xie, and C. Nathan (1997). Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350.
52. D. A. Wink, Y. Vodovotz, J. Laval, F. Laval, M. W. Dewhirst, and J. B. Mitchell (1998). The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19:711-721.
53. J. K. Ruohola, T. P. Viitanen, E. M. Valve, J. A. Seppanen, N. T. Loponen, J. J. Keskitalo, P. T. Lakkakorpi, and P. L. Harkonen (2001). Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 61:4229-4237.
54. D. G. Fernig, H. L. Chen, H. Rahmoune, S. Descamps, B. Boilly, and H. Hondermarck (2000). Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. Biochem. Biophys. Res. Commun. 267:770-776.
55. J. Nagy, G. W. Curry, K. J. Hillan, I. C. McKay, E. Mallon, A. D. Purushotham, and W. D. George (1996). Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg. Oncol. 5:15-21.
56. J. A. Leal, B. K. Gangrade, J. L. Kiser, J. V. May, and B. A. Keel (1991). Human mammary tumor cell proliferation: Primary role of platelet-derived growth factor and possible synergism with human alpha-fetoprotein. Steroids 56:247-251.
57. H. Nagaoka, Y. Iino, H. Takei, and Y. Morishita (1998). Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in macrophages correlates with tumor angiogenesis and prognosis in invasive breast cancer. Int. J. Oncol. 13:449-454.
58. N. Jonjic,T. Valkovic, K. Lucin, Z. Iternicka, M. Krstulja, E. Mustac, R. Dobi-Babic, F. Sasso, and M. Melato (1998). Comparison of microvessel density with tumor associated macrophages in invasive breast carcinoma. Anticancer Res. 18:3767-3770.
59. D. Toomey, J. Harmey, C. Condron, E. Kay, and D. Bouchier-Hayes (1999). Phenotyping of immune cell infiltrates in breast and colorectal tumors. Immunol. Invest. 28:29-41.
60. A. K. Madan, K. Yu, N. Dhurandhar, C. Cullinane, Y. Pang, and D. J. Beech (1999). Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol. Rep. 6:607-609.
61. P. Bertrand, N. Girard, C. Duval, J. d'Anjou, C. Chauzy, J. F. Menard, and B. Delpech (1997). Increased hyaluronidase levels in breast tumor metastases. Int. J. Cancer 73:327-331.
62. D. Liu, E. Pearlman, E. Diaconu, K. Guo, H. Mori, T. Haqqi, S. Markowitz, J. Willson, and M. S. Sy (1996). Expression of hyaluronidase by tumor cells induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 93:7832-7837.
63. J. Folkman (1990). What is the evidence that tumors are angiogenesis dependent. J. Natl. Cancer Inst. 82:4-6.
64. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1-8.
65. A. H. Lee, L. C. Happerfield, L. G. Bobrow, and R. R. Millis (1997). Angiogenesis and inflammation in invasive carcinoma of the breast. J. Clin. Pathol. 50:669-673.
66. A. H. Lee, L. C. Happerfield, R. R. Millis, and L. G. Bobrow (1996). Inflammatory infiltrate in invasive lobular and ductal carcinoma of the breast. Br. J. Cancer 74:796-801.
67. S. M. Pupa, R. Bufalino, A. M. Invernizzi, S. Andreola, F. Rilke, L. Lombardi, M. I. Colnaghi, and S. Menard (1996). Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J. Clin. Oncol. 14:85-94.
68. J. S. Ross and J. A. Fletcher (1999). HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112:S53-S67.
69. W. R. Bezwoda (2000). c-erb-B2 expression and response to treatment in metastatic breast cancer. Med. Oncol. 17:22-28.
70. M. Cazin, D. Paluszezak, A. Bianchi, J. C. Cazin, C. Aerts, and C. Voisin (1990). Effects of anaerobiosis upon morphology and energy metabolism of alveolar macrophages cultured in gas phase. Eur. Respir. J. 3:1015-1022.
71. J. S. Lewis, R. J. Landers, J. C. Underwood, A. L. Harris, and C. E. Lewis (2000). Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J. Pathol. 192:150-158.
72. J. H. Harmey, E. Dimitriadis, E. Kay, H. P. Redmond, and D. Bouchier-Hayes (1998). Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann. Surg. Oncol. 5:271-278.
73. N. S. Brown, A. Jones, C. Fujiyama, A. L. Harris, and R. Bicknell (2000). Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 60:6298-6302.
74. D. W. Miles, L. C. Happerfield, M. S. Naylor, L. G. Bobrow, R. D. Rubens, and F. R. Balkwill (1994). Expression of tumor necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int. J. Cancer 56:777-782.
75. H. Eda, K. Fujimoto, S. Watanabe, M. Ura, A. Hino, Y. Tanaka, K. Wada, and H. Ishitsuka (1993). Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol. 32:333-338.
76. R. D. Leek, R. Landers, S. B. Fox, F. Ng, A. L. Harris, and C. E. Lewis (1998). Association of tumor necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer 77:2246-2251.
77. R. Hildenbrand, G. Wolf, B. Bohme, U. Bleyl, and A. Steinborn (1999). Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J. Leukoc. Biol. 66:40-49.
78. R. Hildenbrand, I. Dilger, A. Horlin, and H. J. Stutte (1995). Urokinase and macrophages in tumor angiogenesis. Br. J. Cancer 72:818-823.
79. R. Hildenbrand, C. Jansen, G. Wolf, B. Bohme, S. Berger, G. von Minckwitz, A. Horlin, M. Kaufmann, and H. J. Stutte (1998). Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast. Lab. Invest. 78:59-71.
80. R. A. Walker, S. J. Bearing, and B. Gallacher (1994). Relationship of transforming growth factor beta 1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br. J. Cancer 69:1160-1165.
81. D. Toomey, C. Condron, Q. D. Wu, E. Kay, J. Harmey, P. Broe, C. Kelly, and D. Bouchier-Hayes (2001). TGF-beta1 is elevated in breast cancer tissue and regulates nitric oxide production from a number of cellular sources during hypoxia reoxygenation injury. Br. J. Biomed. Sci. 58:177-183.
82. J. P. Van Netten, B. J. Ashmead, R. L. Parker, I. G. Thornton, C. Fletcher, D. Cavers, P. Coy, and M. L. Brigden (1993). Macrophage-tumor cell associations: A factor in metastasis of breast cancer? J. Leukoc. Biol. 54:360-362.
83. P. R. Crocker, S. Mucklow, V. Bouckson, A. McWilliam, A. C. Willis, S. Gordon, G. Milon, S. Kelm, and P. Bradfield (1994). Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. EMBO J. 13:4490-4503.
84. C. W. Pugh, J. Gleadle, and P. H. Maxwell (2001). Hypoxia and oxidative stress in breast cancer. Hypoxia signalling pathways. Breast Cancer Res. 3:313-317.
85. M. Hampl, T. Tanaka, P. S. Albert, J. Lee, N. Ferrari, and H. A. Fine (2001). Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum. Gene Ther. 12:1713-1729.
86. S. A. Im, J. S. Kim, C. Gomez-Manzano, J. Fueyo, T. J. Liu, M. S. Cho, C. M. Seong, S. N. Lee, Y. K. Hong, and W. K. Yung (2001). Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br. J. Cancer 84:1252-1257.
87. M. Kampa, A. Hatzoglou, G. Notas, M. Niniraki, E. Kouroumalis, and E. Castanas (2001). Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ. 8:943-952.
88. S. Pervin, R. Singh, C. L. Gau, H. Edamatsu, F. Tamanoi, and G. Chaudhuri (2001). Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: Implications in breast cancer. Cancer Res. 61:4701-4706.
89. L. C. Jadeski and P. K. Lala (1999). Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am. J. Pathol. 155:1381-1390.
90. L. L. Thomsen and D. W. Miles (1998). Role of nitric oxide in tumor progression: Lessons from human tumors. Cancer Metastasis Rev. 17:107-118.
91. C. Denoyelle, M. Vasse, M. Korner, Z. Mishal, F. Ganne, J. P. Vannier, J. Soria, and C. Soria (2001). Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis 22:1139-1148.
92. D. M. Evans and K. Sloan-Stakleff (2000). Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Am. Surg. 66:460-464.
93. A. Kruger, R. Soeltl, V. Lutz, O. G. Wilhelm, V. Magdolen, E. E. Rojo, P. A. Hantzopoulos, H. Graeff, B. Gansbacher, and M. Schmitt (2000). Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther. 7:292-299.
94. H. Li, H. Lu, F. Griscelli, P. Opolon, L. Q. Sun, T. Ragot, Y. Legrand, D. Belin, J. Soria, C. Soria, M. Perricaudet, and P. Yeh (1998). Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene. Ther. 5:1105-1113.
95. R. J. Tressler, P. A. Pitot, J. R. Stratton, L. D. Forrest, S. Zhuo, R. J. Drummond, S. Fong, M. V. Doyle, L. V. Doyle, H. Y. Min, and S. Rosenberg (1999). Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth. APMIS 107:168-173.
96. R. H. Xing, A. Mazar, J. Henkin, and S. A. Rabbani (1997). Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 57:3585-3593.
97. C. Erlichman, A. A. Adjei, S. R. Alberts, J. A. Sloan, R. M. Goldberg, H. C. Pitot, J. Rubin, P. J. Atherton, G. G. Klee, and R. Humphrey (2001). Phase I study of the matrix metalloproeinase inhibitor, BAY 12-9566. Ann. Oncol. 12:389-395.
98. Y. Jiang, M. Wang, M. Y. Celiker, Y. E. Liu, Q. X. Sang, I. D. Goldberg, and Y. E. Shi (2001). Simulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res. 61:2365-2370.
99. J. Lee, M. Weber, S. Mejia, E. Bone, P. Watson, and W. Orr (2001). A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur. J. Cancer 37:106-113.
100. P. D. Brown (2000). Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin. Investig. Drugs 9:2167-2177.
101. P. D. Brown (1998). Matrix metalloproteinase inhibitors. Breast Cancer Res. Treat. 52:125-136.
102. H. S. Rasmussen and P. P. McCann (1997). Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol. Ther. 75:69-75.
103. F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Fontanini, S. Cuccato, S. De Placido, A. R. Bianco, and G. Tortora (2001). Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7:1459-1465.
104. D. Liu, L. Buluwela, S. Ali, S. Thomson, J. J. Gomm, and R. C. Coombes (2001). Retroviral infection of the FGF2 gene into MCF-7 cells induces branching morphogenesis, retards cell growth and suppresses tumorigenicity in nude mice. Eur. J. Cancer 37:268-280.
105. M. K. Yunmbam and A. Wellstein (2001). The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo. Oncol. Rep. 8:161-164.
106. R. Bagheri-Yarmand, Y. Kourbali, C. Mabilat, J. F. Morere, A. Martin, H. Lu, C. Soria, J. Jozefonvicz, and M. Crepin (1998). The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumor angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br. J. Cancer 78:111-118.
107. N. S. Chang (1998). Transforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review). Int. J. Mol. Med. 2:653-659.
108. G. Baumgartner, C. Gomar-Hoss, L. Sakr, E. Ulsperger, and C. Wogritsch (1998). The impact of extracellular matrix on the chemoresistance of solid tumors - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett. 131:85-99.
109. B. S. Croix, J. W. Rak, S. Kapitain, C. Sheehan, C. H. Graham, and R. S. Kerbel (1996). Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88:1285-1296.
110. M. Jaffar, K. J. Williams, and I. J. Stratford (2001). Bioreductive and gene therapy approaches to hypoxic diseases. Adv. Drug. Deliv. Rev. 53:217-228.
111. G. Perletti, P. Concari, R. Giardini, E. Marras, F. Piccinini, J. Folkman, and E. Chen (2000). Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 60:1793-1796.
112. M. S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, and J. Folkman (1997). Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
113. J. Vukanovic and J. T. Isaacs (1995). Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 55:1499-1504.
114. E. Griffiths, K. Binley, S. Iqball, O. Kan, P. Maxwell, P. Ratcliffe, C. Lewis, A. Harris, S. Kingsman, and S. Naylor (2000). The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene. Ther. 7:255-262.
115. M. Adachi, M. F. Roussel, K. Havenith, and C. J. Sherr (1997). Features of macrophage differentiation induced by p19INK4d, a specific inhibitor of cyclin D-dependent kinases. Blood 90:126-137.
116. K. L. Talks, H. Turley, K. C. Gatter, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. E. Harris (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411-421.
117. H. M. Ogmundsdottir (2001). Immune reaction to breast cancer: For better or for worse? Arch. Immunol. ther. Exp. (Warsz) 49(Suppl. 2):S75-S81.
118. L. A. DiPietro (1995). Wound healing: The role of the macrophage and other immune cells. Shock 4:233-240.
119. D. R. Knighton and V. D. Fiegel (1989). Macrophage-derived growth factors in wound healing: Regulation of growth factor production by the oxygen microenvironment. Am. Rev. Respir. Dis. 140:1108-1111.